• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » InspireMD soars on FDA green light to begin clinical trial

InspireMD soars on FDA green light to begin clinical trial

April 23, 2013 By Arezu Sarvestani

InspireMD logo

Stent technology maker InspireMD (OTC:NSPR) gained a few points on Wall Street today on news that the FDA gave the company a conditional green light to proceed with a clinical trial of its MGuard Embolic Protection Stent.

The FDA concurred with the overall study design, InspireMD said, and minor details are still being hashed out while the company begins initial enrollment in the investigational device exemption study.

The news sent NSPR shares up more than 6% as of 12:30 p.m. when they were trading at $2.09 apiece just a day after InspireMD announced that it raised nearly $23 million from a public stock offering.

"Receiving this approval to commence our FDA trial is a significant milestone," president & CEO Alan Milinazzo said in prepared remarks. "This trial will provide an excellent opportunity to validate the safety and effectiveness of MGuard EPS in another large multi-center, randomized trial, comparing both bare metal and drug eluting stents, the current therapy for STEMI patients."

InspireMD’s MASTER II IDE trial will enroll 1,114 patients at 35 U.S. sites and another 35 sites in Europe, according to a press release. The study is the 2nd in a string of clinical trials evaluating the effectiveness of the MGuard EPS platform in support of various worldwide regulatory submissions.

The company last month announced that it had won CE Mark approval in the European Union for the MGuard blood clot stent.

The study will enroll patients with ST Elevation Myocardial Infarction, evaluating complete ST resolution as well as death and target vessel myocardial infarction. The trial includes a 356-patient substudy evaluating the effect of the MGuard EPS on MRI-measure vessel infarct size, according to the company.

Filed Under: Food & Drug Administration (FDA), News Well, Research & Development, Stents Tagged With: Clinical Trials, InspireMD

More recent news

  • Medtronic escapes $106.5M payment in Colibri TAVR patent suit after court overturns jury verdict
  • RadNet closes iCAD acquisition, expands AI breast‑imaging portfolio
  • Hyperfine reports first commercial sales of next-gen AI-powered Swoop
  • Stereotaxis announces $12.5M offering
  • Nuwellis ends clinical trial of its ultrafiltration tech for heart failure

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy